Mohammed Alzubaidi, MD
Nephrology · Sumter, SCNPI 1912258567
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,100 of the $53,906 with a category attached, or 63.3%. 29 manufacturers reported payments, led by Mallinckrodt Enterprises LLC at 53.6% of the total. Reporting peaked in 2019 at $43,282 and has fallen 99.2% since, to $331 in 2025. Among nephrology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 181 payments — averaging $297.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Enterprises LLC$29K
- Vifor Pharma, Inc.$14K
- Fresenius USA Marketing, Inc.$4K
- Mallinckrodt Hospital Products Inc.$4K
- Nxstage Medical, Inc.$932
- Otsuka America Pharmaceutical, Inc.$392
- plus $2K from 23 others
What the payments were for
- Consulting fees$7,64514%
- Speaking & faculty fees$34,10063%
- Travel & lodging$6,27312%
- Food & beverage$5,84711%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Enterprises LLC | 36 | $28,875 |
| Vifor Pharma, Inc. | 23 | $13,921 |
| Fresenius USA Marketing, Inc. | 12 | $4,106 |
| Mallinckrodt Hospital Products Inc. | 6 | $3,647 |
| Nxstage Medical, Inc. | 8 | $932 |
| Otsuka America Pharmaceutical, Inc. | 8 | $392 |
| AstraZeneca(2 entities) | 13 | $391 |
| Amgen(2 entities) | 15 | $265 |
| GSK | 12 | $215 |
| Calliditas Therapeutics US Inc. | 7 | $151 |
| Abbott | 1 | $133 |
| Novartis | 6 | $122 |
| Alnylam Pharmaceuticals Inc. | 4 | $96 |
| Bayer | 5 | $87 |
| Lilly USA, LLC | 2 | $70 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $69 |
| Sanofi | 4 | $64 |
| Akebia Therapeutics Inc | 3 | $60 |
| Daiichi Sankyo Inc. | 3 | $55 |
| Philips North America LLC | 1 | $39 |
| OPKO Pharmaceuticals, LLC | 2 | $37 |
| Travere Therapeutics, Inc. | 2 | $30 |
| Aurinia Pharma U.S., Inc. | 1 | $29 |
| ANI Pharmaceuticals, Inc. | 1 | $26 |
| Novo Nordisk | 1 | $21 |
| Renalytix AI, Inc. | 1 | $21 |
| EUSA Pharma (US) LLC | 1 | $18 |
| Recordati_rare_diseases_inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$28,517
- Veltassa$13,552
- NXSTAGE SYSTEM ONE$808
- CardioMEMS HF System$133
- FARXIGA$125
- TERLIVAZ$125
- NXSTAGE CARTRIDGE EXPRESS$119
- JYNARQUE$107
How this compares
$53,906 in reported general payments places this provider in the 95th percentile of 180 nephrology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 111 | $251,589 |
| Thiola EcTiopronin | 11 | $139,015 |
| ThiolaTiopronin | 12 | $62,342 |
| AuryxiaFerric Citrate | 23 | $58,534 |
| ProcritEpoetin Alfa | 37 | $33,413 |
| VeltassaPatiromer Calcium Sorbitex | 20 | $26,508 |
| LokelmaSodium Zirconium Cyclosilicate | 18 | $14,892 |
| FarxigaDapagliflozin Propanediol | 19 | $14,370 |
| RetacritEpoetin Alfa-Epbx | 19 | $5,877 |
| Sevelamer Carbonate | 25 | $5,323 |
| Calcium Acetate | 17 | $1,984 |
| Nifedipine ErNifedipine | 51 | $1,853 |
| Telmisartan | 23 | $1,302 |
| Torsemide | 37 | $900 |
| Tamsulosin Hcl | 35 | $709 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $4,106 | $251,589111 claims |
| Akebia Therapeutics IncAuryxia | $60 | $58,53423 claims |
| AstraZenecaLokelma, Farxiga | $391 | $29,26237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 180 nephrology providers in South Carolina.
Other nephrology in Sumter
- Pusadee SuchindaSumter$12K
- James CainSumter$5K
- Jessica ColemanBeaufort$930K
- Moustafa MoustafaOrangeburg$616K
- Harold SzerlipCharleston$229K
- Barry GorlitskyGreenville$195K
- Blake ShustermanGreenville$66K
- Martin WebbBeaufort$66K
- Joshua LipschutzCharleston$44K
- Renee EllisColumbia$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.